dc.contributor.author | Gurler, Nezahat | |
dc.contributor.author | Oksuz, LÜTFİYE | |
dc.date.accessioned | 2021-03-06T13:03:51Z | |
dc.date.available | 2021-03-06T13:03:51Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Oksuz L., Gurler N., "Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics", JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.7, ss.825-831, 2013 | |
dc.identifier.issn | 1972-2680 | |
dc.identifier.other | av_f6d5a543-1e74-4f32-8e73-4f5ccc865a61 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/161709 | |
dc.identifier.uri | https://doi.org/10.3855/jidc.3867 | |
dc.description.abstract | Background: The treatment of methicillin-resistant staphylococcal infections has been a growing problem both in and out of hospitals for the past 30 years. Therefore, there is a need for other antibiotics as an alternative to glycopeptides in the treatment of methicillin-resistant staphylococcal infections. This study investigated the in vitro susceptibility of 49 methicillin-resistant Staphylococcus aureus (MRSA) and 59 methicillin-resistant coagulase negative staphylococci (MRCNS) clinical isolates to daptomiycin, telithromycin, tigecyclin, quinupristin/dalfopristin, and linezolid. | |
dc.language.iso | eng | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | BULAŞICI HASTALIKLAR | |
dc.subject | İmmünoloji | |
dc.title | Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF INFECTION IN DEVELOPING COUNTRIES | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 7 | |
dc.identifier.issue | 11 | |
dc.identifier.startpage | 825 | |
dc.identifier.endpage | 831 | |
dc.contributor.firstauthorID | 92952 | |